W P Steward

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

John Ramage, Alia Ahmed, J. Ardill et al. · Gut · 2011 · 947 citations · Full text

Surgical Oncology, Gastroenteropancreatic Neuroendocrine, Gastroenterology +16

Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production.

Christopher R. Ireson, S Orr, Donald J. L. Jones et al. · PubMed · 2001 · 591 citations

Chemoprevention Strategy, Nutraceutical Ingredient, Pathology +19

Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases—Safety, Pharmacokinetics, and Pharmacodynamics

Lynne Howells, D.P. Berry, P.J. Elliott et al. · Cancer Prevention Research · 2011 · 423 citations · Full text

Chemoprevention Strategy, Srt501 Warrants, Oncology +18

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

Juan W. Valle, Harpreet Wasan, Andre Lopes et al. · The Lancet Oncology · 2015 · 276 citations · Full text

Surgical Oncology, Gastrointestinal Oncology, Medicine +8

Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene

S. Sale, Richard D. Verschoyle, David J. Boocock et al. · British Journal of Cancer · 2004 · 259 citations · Full text